INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,064 | -17.7% | 78 | 0.0% | 0.00% | – |
| Q2 2023 | $4,939 | +16.9% | 78 | 0.0% | 0.00% | – |
| Q1 2023 | $4,224 | +2.3% | 78 | 0.0% | 0.00% | – |
| Q4 2022 | $4,128 | +3.2% | 78 | 0.0% | 0.00% | – |
| Q3 2022 | $4,000 | 0.0% | 78 | 0.0% | 0.00% | – |
| Q2 2022 | $4,000 | -20.0% | 78 | 0.0% | 0.00% | – |
| Q1 2022 | $5,000 | – | 78 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 424,500 | $13,499,000 | 5.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $6,360,000 | 3.70% |
| Asymmetry Capital Management, L.P. | 130,654 | $4,155,000 | 1.90% |
| Altium Capital Management LP | 153,348 | $4,876,000 | 1.82% |
| Sofinnova Investments, Inc. | 848,162 | $26,972,000 | 1.61% |
| Bellevue Group AG | 3,659,919 | $116,386,000 | 1.33% |
| Eversept Partners, LP | 356,235 | $11,328,273 | 1.33% |
| Rhenman & Partners Asset Management AB | 500,000 | $15,900,000 | 1.30% |
| GENERAL AMERICAN INVESTORS CO INC | 347,497 | $11,050,000 | 1.09% |
| WASATCH ADVISORS LP | 6,333,900 | $201,418,000 | 0.99% |